Compare TJX Companies Inc (TJX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TJX Companies Inc vs Zimmer Biomet Holdings Inc — how do they compare? TJX Companies Inc trades at $138.76 (market cap $152.62B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: TJX Companies Inc is far larger — about 9× Zimmer Biomet Holdings Inc's market cap, and TJX Companies Inc pays the higher dividend (1.38%). Which is the better fit depends on your goals — on Pluang, investors hold TJX Companies Inc for 97 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TJX | ZBH | |
|---|---|---|
Market Cap | $152.62B | $16.95B |
Volume | 8,079,794 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $168.41 | $103.98 |
52-Week Low | $122.84 | $79.58 |
Typical Hold Time | 97 Days | 89 Days |
Enterprise Value | $160.93B | $24.02B |
Dividend Yield | 1.38% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TJX trades at $138.75, down slightly by 0.04% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with revenue growing from $48.5B in 2022 to $56.4B in 2025, and net income margin expanding to 8.63%. Recent quarters have consistently beaten EPS expectations, and analysts project a consensus price target of $174.15, implying 28% upside. The stock is supported by robust cash flow from operations of $6.12B in 2025 and a healthy balance sheet with $5.34B in cash.
The outlook for TJX is positive, driven by earnings growth, market share gains in off-price retail, and Wall Street's strong buy consensus. Key risks include competitive pressures, consumer spending volatility, and elevated valuation multiples. The stock presents a compelling opportunity for growth-oriented investors, though near-term technical overbought conditions warrant caution.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
